Avalanche Biotechnologies Inc. (AAVL) is Trading Higher on Unusual Volume for February 11

Equities Staff |

Avalanche Biotechnologies Inc. (AAVL) experienced unusually high volume on Feb. 11, as the stock gained 4.38% to a closing price of $4.77. The stock saw 789,747 shares trade hands over the course of the day on 4,772 trades. Given that the stock’s average daily volume over the last month has been 419,655 shares a day, this represents a pretty substantial spike over the norm.

Avalanche Biotechnologies Inc. has a P/B ratio of 0.47. The stock has traded between $45.18 and $4.00 over the last 52-weeks, its 50-day SMA is now $7.56, and its 200-day SMA $14.81.

Avalanche Biotechnologies Inc is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases.

Headquartered in Menlo Park, CA, Avalanche Biotechnologies Inc. has 73 employees and is currently under the leadership of CEO Paul B. Cleveland.

For a complete fundamental analysis analysis of Avalanche Biotechnologies Inc., check out Equities.com’s Stock Valuation Analysis report for AAVL. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…